Diginex (DGNX) × Resulticks: Probability-Weighted Outcome Analysis Into the June 12 Long-Stop Date

**TL;DR**
• The single most likely outcome by Friday, June 12, 2026 (the confirmed long-stop date) is a THIRD extension, not a completed acquisition. I estimate \~55-60% extend-again, \~15-20% completed-and-announced, \~20-25% termination/lapse. The binding constraint is not the parties’ willingness but Nasdaq listing approval: issuing 141,666,667 new shares onto a \~29.1M share base is an \~83% change of control that very likely forces a fresh initial-listing application carrying a $4.00 minimum bid-price test — versus DGNX’s \~$1.02 price.

• Expected price action: an extension drives roughly -5% to -20% (history: -20.8% on the May 14 extension, -6% on the June 3 update); a completion announcement triggers a violent low-float pop (+30% to +150% intraday) that likely fades on dilution reality; a termination/lapse drives -35% to -60% and re-exposes a $3.57M-revenue micro-cap to a September delisting clock.

• Most likely near-term press releases: a long-stop-date update on/around June 12 (extension most probable), continued near-weekly product/partnership/ESG releases (the cadence is high), a half-year results release (\~July), a Nasdaq-compliance update, and possibly a renewed ADX/Abu Dhabi dual-listing or capital-raise update.

**Key Findings**

1. The long-stop date is confirmed as June 12, 2026 — this Friday. Per the SPA dated April 16, 2026 and Diginex’s Form 6-K furnished May 29, 2026: “The Parties today agreed to extend the Long Stop Date in the SPA from May 29, 2026 to June 12, 2026. The extension is intended to provide the Parties additional time to satisfy the remaining closing conditions related to the Acquisition.” The user’s premise is correct.
2. The deal has slipped twice. (a) The April 16 announcement guided to closing “within the next 30-45 days subject to closing conditions.” (b) On May 14, 2026 the parties “mutually agreed to extend the Long Stop date for Closing to May 29, 2026” — DGNX fell 20.8% that session. (c) On May 29 (6-K) and reiterated June 3, the date moved to June 12, 2026 — the stock fell \~6% on the June 3 update.
3. Deal terms. All-share transaction valued at US$1.5 billion. Originally 1,133,333,333 new shares at a $1.32 reference price; after an 8-for-1 reverse consolidation effective April 28, 2026, per Diginex’s May 1, 2026 clarification “the pre-consolidation consideration share issuance of 1,133,333,333, is therefore adjusted to 141,666,667 shares on a post-consolidation basis (1,133,333,333 / 8),” with the reference price “adjusted to US$10.56 per share (US$1.32 \* 8) … versus close price on April 30th, 2026 of US$1.82.” The original June 5, 2025 MOU had valued Resulticks at $2.0B (cash-and-stock with earnouts: $1.4B stock at $72/share, $100M cash, plus a $200M growth-funding commitment) — the deal was materially restructured down and to all-stock. Diginex also agreed that 85% of any capital injections through March 31, 2027 (up to $200M) will fund Resulticks.
4. Closing conditions create a structural bottleneck. Per the 6-K, closing requires: shareholder approval of the share issuance, Nasdaq approval to list the consideration shares, regulatory and third-party consents, governance changes, and cancellation of substantially all founder warrants. Shareholder approval is already secured — at the April 13, 2026 EGM the M&A/authorized-capital proposals passed with \~99.6% of votes cast (99.607% on the principal proposal) on 43.579% turnout (101,346,084 of 232,557,527 eligible shares). That leaves Nasdaq listing approval as the critical-path item.
5. The likely real reason for the repeated delays: Nasdaq Rule 5110(a) change-of-control / “back-door listing.” Issuing 141.7M shares onto \~29.1M outstanding gives Resulticks holders \~83% of the combined company — far above the \~20% ownership/voting threshold Nasdaq’s Listing Council (Decision 2018-4) treats as the practical trigger for Rule 5110(a). Rule 5110(a) requires a company that “combines with a non-Nasdaq entity, resulting in a change of control” to “apply for initial listing” and satisfy ALL initial-listing criteria — including the $4.00 minimum bid price under Rule 5505(a)(1)(A), versus the $1.00 continued-listing minimum under Rule 5550(a)(2). Enforcement precedents (Onconetix/Proteomedix, Premier Exhibitions, BioSante, Zhone) show sub-$4 acquirers forced into reverse splits or facing delisting determinations on exactly this point; in the Onconetix case Nasdaq expressly stated the combination “results in a ‘Change of Control’ pursuant to Nasdaq Listing Rule 5110(a)” requiring satisfaction of “a minimum price per share of at least $4.00.” No DGNX filing explicitly names Rule 5110(a), so this is a strong, precedent-backed inference — but it cleanly explains why a deal with shareholder approval already in hand keeps slipping: at \~$1, DGNX cannot clear a $4 initial-listing bid-price test.
6. DGNX is a distressed, low-float, high-volatility micro-cap. Price \~$1.02 (June 9, 2026); market cap \~$30M; \~29.1M shares outstanding post-split; cash just $1.85M (most recent quarter); TTM revenue \~$3.57M; net loss \~$9.86M; beta 2.44. Short interest \~2.7M shares = \~23.8% of float, \~2.3 days to cover. The stock is down \~98% over twelve months (52-week range $0.89–$318.84 on a split-adjusted basis). It also faces a separate Nasdaq continued-listing deficiency: a March 23, 2026 letter from Nasdaq’s Listing Qualifications Department cited breach of Rule 5550(a)(2) (closing bid below $1.00 for 30 consecutive business days); the 180-day cure period ends September 21, 2026 (must close ≥$1.00 for 10 consecutive days), with a possible additional 180-day grace period.
7. Founder alignment is real but has not supported the price. Chairman Miles Pelham reports investing US$25.4M since the IPO at an average of US$5.69/share (\~4.7x the current price); at \~$1.07 that stake is now worth roughly $4.8M. Rhino Ventures (Pelham-controlled) holds 4,170,520 warrants “exercisable at a price of US$6.13 per warrant … \[which\] if fully exercised, will result in the issuance of Ordinary Shares in an amount equal to 51% of the Company’s outstanding Ordinary Shares” (118,604,339 shares per Schedule 13D/A Amendment No. 5) — themselves a major overhang/control feature, and their cancellation is a closing condition.

**Details**
Trading microstructure and reaction history. DGNX behaves as a binary, headline-driven low-float instrument. Reverse-split day (April 28) swung between $2.40 and $4.99 and closed $2.72, then collapsed to \~$0.45 within days as the mechanical split failed to hold. Acquisition-tagged headlines have averaged roughly -7% with a range from +7.4% to -18.4%; AI/deal updates have repeatedly been sold (three of four AI-tagged events saw double-digit declines). Ahead of the prior (May 29) deadline, the stock rallied \~19% intraday to as high as $1.50 on no news — pure event speculation — then faded. This pattern matters: pre-deadline rallies driven by retail “completion” bets tend to reverse on extension headlines.
Financing/dilution math. This is an all-stock deal, so Diginex’s $1.85M cash position is not the gating issue for consideration — but it is critically thin for operating burn (\~$9.9M annual loss) and for the $200M Resulticks growth-funding commitment, which presupposes external capital (the lapsed ADX/Nomas $250M raise was the intended source). If completed, the 141.7M consideration shares represent \~83% dilution; existing holders would own \~17% of an entity whose acquired revenue ($150M) dwarfs DGNX’s standalone (\~$3.6M). The market’s persistent \~$1 price against a $10.56 deal reference price signals deep skepticism that the deal closes on stated terms.
Resulticks fundamentals. A Singapore-headquartered (with US/India/Middle East operations) real-time, AI-driven omnichannel customer-engagement platform led by co-founder/CEO Redickaa Subrammanian. Per Diginex’s June 3, 2026 6-K, “Resulticks is expected to contribute approximately $150 million in annual revenue and $46–50 million in EBITDA, subject to completion,” with management citing \~32% EBITDA margin, \~70% five-year revenue CAGR, and projecting $190-210M (2026) and $250-280M (2027). Third-party trackers (Owler, Datanyze, Growjo) show materially smaller revenue estimates (\~$25-100M) and \~215-250 employees, so the cited figures are management/deal-marketing numbers, not independently audited in the public record. No regulatory, antitrust, or shareholder-vote obstacle on the Resulticks side has been reported; the friction is on the Diginex/Nasdaq side.
Other catalysts and PR cadence. Diginex runs an unusually heavy press cadence (multiple releases per week): product launches (e.g., “Risk-to-Remedy” supply-chain suite, June 4), subsidiary milestones (Matter carbon-automation, May 28), executive appointments, investor interviews, and “corporate update” pieces. The ADX (Abu Dhabi Securities Exchange) dual-listing with Nomas Global Investments (an SPV of Abu Dhabi royal H.H. Shaikh Mohammed Bin Sultan Bin Hamdan Al Nahyan), plus an associated up-to-$250M capital raise, has been repeatedly delayed since the March 2025 MOU and remains a wildcard catalyst. A half-year/quarterly results release is expected around July.
Recommendations
Base case to assess against: another extension. Treat \~55-60% probability that on/around June 12 Diginex announces a further extension (likely another short window) rather than completion. The tell will be a 6-K/press release using the now-familiar “additional time to satisfy the remaining closing conditions” language.
Staged framework and thresholds that would change the view:
• Bullish trigger (raise completion odds toward 40%+): DGNX closing ≥$4.00 for several consecutive sessions (clearing the inferred initial-listing bid-price hurdle), OR an explicit disclosure that Nasdaq has approved the listing application / waived a 5110(a) initial-listing requirement, OR a further large reverse split announced specifically to enable the deal. Absent one of these, completion by Friday is unlikely.
• Bearish trigger (raise termination odds): Resulticks/seller-side commentary going quiet, removal of the deal from forward guidance, an auditor/going-concern flag in the next results, or a Nasdaq delisting-determination letter. Any of these should be treated as deal-break signals.
• Event-risk posture: Because the stock front-runs the date with speculative rallies that reverse on extension news, the asymmetry into Friday favors fade-the-rally over chase-the-breakout unless a bullish trigger above appears. A completion headline can still produce a sharp short-squeeze pop (high short interest, \~2.3 days to cover, tiny float) — size accordingly and expect the pop to fade on dilution.
• Position sizing: Treat any exposure as a binary option on a distressed micro-cap, not an investment in fundamentals; standalone DGNX is a \~$3.57M-revenue, \~$1.85M-cash company burning \~$10M/yr with a September delisting clock.
Expected price ranges by scenario (calibrated, wide):
• Completion announced on/around June 12 (\~15-20%): +30% to +150% intraday squeeze, likely fading toward +0% to +40% within days as \~83% dilution and lock-up structure are absorbed; high path-dependency.
• Another extension (\~55-60%): -5% to -20% (modal -10%), consistent with the -20.8% (May 14) and -6% (June 3) precedents; magnitude depends on how much speculative premium built up pre-date.
• Termination/lapse (\~20-25%): -35% to -60%, removing the entire bull narrative and leaving a delisting-threatened shell; possible disorderly gaps given thin liquidity.
Caveats
• This is a speculative, manipulation-prone low-float stock. Intraday ranges of 2-4x have occurred; point price targets are unreliable and ranges are deliberately wide.
• The Rule 5110(a) thesis is an inference, not a confirmed disclosure. No Diginex filing or Nasdaq notice in the public record explicitly states the deal is a 5110(a) change of control requiring a $4 initial-listing application. It is strongly supported by the \~83% ownership shift, the rule’s text, and close precedents — and it best explains the repeated delays despite shareholder approval — but it could be wrong, and the documented closing condition is simply “Nasdaq approval to list the new shares.”
• Resulticks’ financials are management/deal figures. The $150M revenue / $46-50M EBITDA / 70% CAGR numbers are company-sourced and inconsistent with smaller third-party estimates; they are not independently verified here.
• Probabilities are judgment-based, reflecting two prior slips, the structural Nasdaq hurdle, the persistent \~10x gap between market and deal reference price, and both parties’ repeated stated commitment. New information (a large reverse split, a Nasdaq letter, a capital raise, or seller-side signals) could shift them materially.
• Forward-looking company statements (revenue targets, EBITDA contribution, “absolute confidence”) are explicitly hedged as forward-looking and “subject to completion” in Diginex’s own disclosures.